Technology, Training and Connection Shape the Future of Diabetes Care at ICLDEC’s 3rd Annual Diabetes Education & Technology Conference

  • 3rd edition of the Diabetes Education & Technology Conference positions Abu Dhabi at the forefront of diabetes education and innovation
  • Conference spotlights the latest advances in diabetes technology, from CGM and AID systems to the growing impact of artificial intelligence in care
  • New hands-on workshop format introduced in response to delegate feedback, providing practical training on leading diabetes technologies

Abu Dhabi, United Arab Emirates, June 26: M42’s Imperial College London Diabetes & Endocrine Centre (ICLDEC), together with HealthPlus Diabetes & Endocrinology Centre, successfully hosted the 3rd Diabetes Education & Technology Conference at Grand Hyatt Abu Dhabi on the 20 and 21st of June, reaffirming its role as a leading platform for advancing diabetes education and technology in the UAE.

The conference welcomed more than 500 attendees and over 30 faculty members, reflecting growing demand for practical, multidisciplinary education in diabetes technology. Healthcare professionals from nursing, dietetics, pharmacy, diabetes education, and allied health came together to explore the technologies transforming diabetes care today. This year’s edition also introduced four hands-on workshops in response to delegate feedback and designed to bridge the gap between technological innovation and real-world clinical practice.

Globally, 589 million adults (aged 20–79) are living with diabetes, which equates to approximately 1 in 9 people worldwide[1]. The conference addressed the need for healthcare professionals to stay current with rapidly evolving technologies while ensuring their effective use in patient care. Reflecting this need, discussions focused on technologies that are not only new, but also practical, scalable and ready for clinical adoption, from artificial intelligence and digital health solutions to continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems.

Dr. Mai Ahmed Al Jaber, CEO of Outpatient Care Cluster at M42, said: “Innovation in diabetes care is moving quickly, but it only creates value when healthcare professionals feel confident using it in practice. Conferences such as this help educate, strengthen collaboration across disciplines and support the adoption of innovations that can improve patient care. We are proud to ongoingly bring together clinicians from across disciplines to share knowledge, build practical skills, and help translate innovation into better support for people living with diabetes in the UAE and beyond.”

The conference also emphasised the importance of peer exchange and professional dialogue in a field evolving as rapidly as diabetes technology. Through a mix of expert presentations and hands-on workshops, delegates had the opportunity to share perspectives, learn from real clinical experiences, and strengthen their ability to apply emerging tools in day-to-day practice.

Dr Tomader Ali, Manager Diabetes Education at Outpatient Care Cluster at M42, said: “In diabetes education, relevance matters as much as expertise. We designed this year’s conference to give delegates practical exposure to a range of clinically relevant digital technology tools that enable the enhancement of alogrithm-driven decisions and conversations shaping care today. We aim for our colleagues and attendees to leave not only informed, but to be better prepared for everyday clinical practice in our increasingly AI-demanding patient care. It is exciting to see how strongly this has resonated nationally, and we look forward to building on that momentum in future editions of the conference.”

Dr. Imad Alostaz, Manager, Pharmacy Services, Outpatient Cluster, M42, said “What stood out was how practical and relevant the conference was, both in the quality of the content and in the opportunity to learn from peers across the profession. I look forward to future editions and to continuing these important conversations.”

As the UAE continues to strengthen its position as a regional hub for healthcare innovation, initiatives such as the Diabetes Education & Technology Conference play an important role in strengthening professional education, fostering multidisciplinary collaboration and supporting the practical adoption of technologies that can enhance diabetes care.

By investing in education, innovation and knowledge-sharing, ICLDEC and HealthPlus Diabetes and Endocrinology Center [JM1] are helping equip healthcare professionals with the expertise needed not only to keep pace with change, but to help shape the future of diabetes care in the UAE.

– ENDS –

About the Imperial College London Diabetes & Endocrine Centre

Imperial College London Diabetes & Endocrine Centre (ICLDEC), an M42 company, is a state-of-the-art outpatient facility that specialises in diabetes treatment, research, training, and public health awareness. In just over a decade, the Centre has gained international renown for its holistic approach to the treatment of diabetes and related complications that enables patients to receive the full spectrum of care they need in one place.

With more than 80 diabetes professionals and endocrinologists under one roof, Imperial College London Diabetes & Endocrine Centre offers best-in-class medical attention from first diagnosis to disease management across 11 specialist practice areas including adult and paediatric endocrinology, treatment of metabolic and electrolyte disorders, pre- and post-bariatric surgery care, heart disease prevention, nutritional advice, diabetes education services, ophthalmology, nephrology, and podiatry.

ICLDEC was established in 2006 in Abu Dhabi by Mubadala in partnership with the UK’s Imperial College London to address the growing demand for diabetes care in the UAE. The centre now operates four branches across Abu Dhabi, Al Dhafra and Al Ain, touching the lives of more than one million people through patient-centric programmes and public health initiatives. In 2007, ICLDEC launched Diabetes. Knowledge. Action, now the longest running public health awareness campaign in the country. The initiative promotes an active lifestyle through an ongoing calendar of events for the whole community.

ICLDEC holds the Joint Commission International (JCI) Clinical Care Program Certification in Outpatient Diabetes Management and JCI Accreditation for Ambulatory Care.

For more information, please visit www.icldec.ae

About HealthPlus Diabetes & Endocrinology Center

Part of HealthPlus Network of Specialty Centers, the HealthPlus Diabetes & Endocrinology Center, part of M42, has established itself as a Center of Excellence in Diabetes Care through its multi-disciplinary approach to diabetes management and treatment. With a focus on patient care, clinical outcomes, education and training, HealthPlus Diabetes & Endocrinology Center philosophy is at the forefront of the latest medical advances, providing the best available evidence-based diabetes and endocrine treatments consistently and effectively to its patients. The center’s specialties include Diabetology, Endocrinology, Ophthalmology, Cardiology, Internal Medicine, Podiatry, Psychiatry, Nutrition, Dermatology and more.

About M42

M42 is a global health champion powered by artificial intelligence (AI), technology and genomics to advance innovation in health for people and the planet. Headquartered in Abu Dhabi, M42 combines its specialized, state-of-the-art facilities with integrated health solutions like genomics and biobanks, and harnesses advanced technologies to deliver precise, preventive and predictive care, to impactfully disrupt traditional healthcare models and positively impact lives globally.

Established in 2023, following the coming together of G42 Healthcare and Mubadala Health, M42 has more than 480 facilities in 26 countries and over 20,000 employees. M42 includes renowned healthcare providers including Cleveland Clinic Abu Dhabi, Danat Al Emarat, Diaverum, Imperial College London Diabetes Centre, Sheikh Sultan bin Zayed Hospital, and Moorfields Eye Hospital Abu Dhabi. As well as operating the Emirati Genome Programme, M42 runs Abu Dhabi BioBank and Abu Dhabi Health Data Services (ADHDS), a global tech-enabled healthcare company operating Malaffi.

[1] International Diabetes Federation

 [JM1]HealthPlus Diabetes and Endocrine Center